Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ribavirin in hepatitis

CaHeja, J.L., Albillos, A., Moreno-Otero, R., Rossi, L, Cacho, G., Domper, F., Yebra, M., Escartin, P. Sustained response to interferon-a or to interferon-a plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment. Pharmacol. Ther. 1999 13 1179-1186... [Pg.713]

Sagir A, Wettstein M, Heintges T, Haussinger D. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci 2002 47(3) 562-3. [Pg.1825]

Bessis D, Luong MS, Blanc P, Chapoutot C, Larrey D, Guilhou JJ, GuiUot B. Straight hair associated with inter-feron-alfa plus ribavirin in hepatitis C infection. Br J Dermatol 2002 147(2) 392-3. [Pg.1827]

Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, et al. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2013 43(7) 691-701. [Pg.435]

Jacobson IM, Everson GT, Gordon SC, Kauffman R, McNair L, Muir A, McHutchison JG (2007) Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive subjects with hepatitis C. AASLD 58th Annual Meet, Abstract 177 Johnson M (2006) Response to Atazanavir/ritonavir versus lopinavir/ritonavir equivalent or different efficacy profiles by HUl. AIDS 20 1987... [Pg.105]

Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, PeUiceUi A, Grisorio B, Barbarini G (1999) Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol 34 928-933... [Pg.230]

Gunsar E, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, liter T, Batur Y (2005) Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 10 721-726 Habersetzer E, Boyer N, MarceUin P, Badly F, Ahmed SN, Alam J, Benhamou JP, Trepo C (2000) A pdot study of recombinant interferon beta-la for the treatment of chronic hepatitis C. Liver 20 437 41... [Pg.234]

Lindahl K, Stable L, Bruchfeld A, Schvarcz R (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41 275-279... [Pg.237]

Niro GA, Rosina F, Rizzetto M (2005b) Treatment of hepatitis D. J Viral Hepat 12 2-9 Niro GA, Ciancio A, Gaeta GB, SmedUe A, Marrone A, OUvero A, Stanzione M, David E, Bran-caccio G, Fontana R, Perri F, AndriuUi A, Rizzetto M (2006) Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44 713-720... [Pg.238]

Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F (2004) Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 140(l) 72-73... [Pg.342]

Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, Lohmann V, SchonbergerB, Zeuzem S, Sarrazin C (2007) Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology I32(3) 92I-930... [Pg.343]

Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15) 1521-1531 Lindahl K, Stable L, Bruchfeld A, Schvarcz R (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41(2) 275-279... [Pg.344]

Zeuzem S, Buti M, Ferenci P, Sped J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, NovieUo S, Brass C, Albrecht J (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44(1) 97-103... [Pg.346]

In general, cautiously administer ribavirin capsules to elderly patients, starting at the lower end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Do not use ribavirin in elderly patients with Ccr less than 50 mL/min. [Pg.1781]

F. Role in therapy According to Micromedex, current agents of choice in the treatment of chronic hepatitis C are interferon alfa-2a, alfa-2b,alfacon-l, peginterferon alfa-2b, or alfa-2b plus ribavirin. Efficacy of these interferons is similar, although response rates have been higher with the addition of oral ribavirin. In a... [Pg.206]

Disis ML, Feld JJ Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005 436 967. [Pg.1209]

Sauvage FL, Stanke-Labesque F, Gagnieu MC, Jourdil JF, Babany G, Marquet P (2009) Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. Ther Drug Monit 31 374-381... [Pg.125]

Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 443-51. [Pg.711]

Perez-Calvo, J., Lasierra, R, Moros, M., Inigo, R Role of ribavirin in membranoproliferative glomerulonephritis associated with hepatitis C... [Pg.457]

Bajaj, J.S., Molina, E., Regev, A., Schiff, E.R., Jeffers, L.J. Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2b and ribavirin in chronic hepatitis C. Gastrointest. Endosc. 2003 58 380- 383... [Pg.713]

Asymptomatic prolongation of the activated partial thromboplastin time associated with Inpus anticoagulant and a reduction in the coagulation activity of factors IX, XI, and XII occurred after 10 weeks of interferon alfa-2b and ribavirin in a 60-year-old woman with chronic hepatitis C (236). There were no arguments in favor of an antiphospholipid syndrome, and all the abnormalities normalized after withdrawal. [Pg.1807]

Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci 2001 322(4) 233-5. [Pg.1819]

Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C a series of 20 patients. Br J Dermatol 2002 147(6) 1142-6. [Pg.1827]

The adverse effects and other safety aspects of interferon and ribavirin in the treatment of hepatitis C infection have been reviewed (10). [Pg.3037]

As part of a multicenter, randomized, double-blind, placebo-controlled trial of ribavirin in 59 patients with hepatitis C virus infection, liver biopsies were studied for iron deposition (19). Increased total iron deposition, preferentially in hepatocytes, occurred during a 9-month course of ribavirin. The deposition had no apparent effect on the biochemical or histological response to ribavirin therapy. [Pg.3038]

Herrmann E, Lee J, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003 37 1351-8. [Pg.1834]

N. M. Dixit, J. E. Layden-Almer, T. J. Layden, and A. S. Perelson, Modelhng how ribavirin improves interferon response rates in hepatitis c virus infection. Nature 432 922-924... [Pg.596]

See other pages where Ribavirin in hepatitis is mentioned: [Pg.236]    [Pg.144]    [Pg.236]    [Pg.144]    [Pg.313]    [Pg.110]    [Pg.230]    [Pg.231]    [Pg.235]    [Pg.237]    [Pg.238]    [Pg.238]    [Pg.242]    [Pg.341]    [Pg.313]    [Pg.183]    [Pg.1148]    [Pg.347]    [Pg.658]    [Pg.879]    [Pg.884]    [Pg.590]    [Pg.599]   
See also in sourсe #XX -- [ Pg.280 , Pg.281 ]

See also in sourсe #XX -- [ Pg.280 , Pg.281 ]

See also in sourсe #XX -- [ Pg.753 , Pg.754 ]



SEARCH



In hepatitis

Ribavirin in chronic hepatitis

© 2024 chempedia.info